• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Re­searchers call for fi­nan­cial in­cen­tives to speed con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

3 years ago
R&D

Gilead teams with CNN for poignant do­cuseries about the lives of HIV ad­vo­cates in south­ern US states 

3 years ago
Pharma
Marketing

New Jer­sey judge de­cides Bausch Health's Xi­fax­an is 'pri­or art,' does not in­fringe Cu­ria patents

3 years ago
Pharma
Law

Man­u­fac­tur­ing roundup: As­traZeneca and Sam­sung ink $350M deal; Michi­gan CD­MO com­pletes ex­pan­sion

3 years ago
Manufacturing

Cipla man­u­fac­tur­ing site in In­dia lands a Form 483 for un­clean equip­ment, lack of da­ta

3 years ago
Pharma
FDA+

Mil­lions more mon­key­pox vac­cine and an­tivi­ral cours­es com­ing to states next week, but will it be enough?

3 years ago
Pharma
FDA+

Through the lymph nodes it goes — re­searchers de­vel­op a can­cer drug that avoids tox­i­c­i­ties by skirt­ing the liv­er

3 years ago
R&D
Discovery

Al­mac com­mits to $65M ex­pan­sion for its Penn­syl­va­nia HQ amid wider in­vest­ments

3 years ago
Financing
Pharma

FDA lifts par­tial hold on Curis' lym­phoma study — shares spike

3 years ago
FDA+

Astel­las' hot flash­es drug will get speedy re­view at FDA; US opts out of Val­ne­va vac­cine

3 years ago
News Briefing

Those big bil­lion-dol­lar PhI­II stud­ies? Mar­tin Lan­dray says they can be done for a tiny frac­tion of the cost

3 years ago
R&D
In Focus

Up­dat­ed: 'Se­mi-re­tired' an­a­lyst Ge­of­frey Porges de­parts SVB to lead fi­nances at a drug dis­cov­ery shop

3 years ago
People

Roche, Genen­tech plunk down $60M up­front to part­ner with Chi­nese phar­ma on PRO­TAC-based prostate can­cer drug

3 years ago
Deals
China

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

3 years ago
Deals
AI

CSL CEO Paul Per­reault de­ter­mined to grow plas­ma col­lec­tion af­ter full-year sales dip

3 years ago
Pharma

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

3 years ago
Pharma
Marketing

En­do files for Chap­ter 11 as it looks to fin­ish off its opi­oid lit­i­ga­tion

3 years ago
Pharma
Law

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

3 years ago
People
Pharma

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

3 years ago
Deals

FDA ap­proves one of the prici­est new treat­ments of all time — blue­bird's gene ther­a­py for be­ta tha­lassemia

3 years ago
Cell/Gene Tx

WuXi STA breaks ground on Delaware fa­cil­i­ty, boost­ing its US pres­ence

3 years ago
Pharma
Manufacturing

So­lo Jonas broth­er car­ries Merz's new tune in Botox ri­val cam­paign

3 years ago
Pharma

Gen­mab launch­es cor­po­rate cam­paign am­pli­fy­ing its ‘knock your socks off’ an­ti­bod­ies

3 years ago
Pharma
Marketing

For­mer Google CEO’s VC is mak­ing a big­ger push in­to the biotech world, hir­ing promi­nent Ther­a­nos skep­tic

3 years ago
People
Financing
First page Previous page 471472473474475476477 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times